Bristol-Myers Squibb Co (BMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
314
About the Report
About the Report
Summary
Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects. The company offers its products across the world to retail pharmacies, wholesalers, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, Japan and other countries. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
Bristol-Myers Squibb Co (BMY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Bristol-Myers Squibb Co, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16
Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 18
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deal Details 31
Asset Purchase 31
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 31
Venture Financing 33
IFM Tre Raises USD31 Million in Series A Venture Financing 33
Enterome Bioscience Raises USD38.5 Million in Series D Financing 34
TARIS Biomedical Raises USD25 Million in Series B Financing 36
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 38
Cardior Pharma Raises USD16.3 Million in Series A Financing 40
IFM Therapeutics Raises USD27 Million in Series A Financing Round 42
Blade Therapeutics Raises USD27 Million in Series B Financing 43
IFM Therapeutics Raises Funds in Seed Financing Round 45
Padlock Therapeutics Raises USD23 Million in Extended Series A Financing 46
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 47
iPierian Raises USD1 Million in Venture Financing 48
Padlock Therapeutics Raises Funds through Series A Financing 49
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 50
iPierian Raises USD 30 Million In Series A Venture Financing 51
Cormorant Pharma Raises USD 2.6 Million In Venture Financing 53
Cardioxyl Pharma Raises USD 28 Million In Series B Financing 54
Private Equity 55
Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 55
Partnerships 57
Bristol-Myers Squibb and Tsinghua University Enter into Co-Development Agreement 57
Bristol-Myers Squibb and Gritstone Oncology Enter into Research Agreement 58
Clinigen and Bristol-Myers Squibb Enter into Agreement 59
Bristol-Myers Squibb Expands Collaboration with Flatiron Health 60
Advantagene Enters into Agreement with Bristol-Myers Squibb 61
Lupus Therapeutics Enters into Agreement with Bristol-Myers Squibb 62
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 63
Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 64
Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 65
Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 66
Replimune Enters into Co-Development Agreement with Bristol-Myers Squibb 68
Sirenas Enters into Research Agreement wiith Bristol-Myers Squibb 69
Taris Biomedical and Bristol-Myers Squibb Enter into Partnership 70
Bristol-Myers Squibb Enters into Research Agreement with Kumamoto University 71
AbbVie and Bristol-Myers Squibb Enter into Agreement 72
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 73
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 74
Bristol-Myers Squibb Enters into Partnership with Novartis 75
Bristol-Myers Squibb and Qiagen Enter into Agreement 76
Advaxis and Bristol-Myers Squibb Enter into Agreement 77
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 78
Bristol-Myers Squibb Enters into Research Agreement with Transgene 79
Bristol-Myers Squibb Enters into Agreement with Nordic Bioscience 80
Bristol-Myers Squibb Enters into Agreement with Apexigen 81
Bristol-Myers Squibb and Incyte Enter into Agreement 82
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 83
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 84
Exelixis Enters into Agreement with Bristol-Myers Squibb 85
Bristol-Myers Squibb Enters into Research Agreement with GeneCentric Diagnostics 86
Janssen Biotech Enters into Partnership with Bristol-Myers 87
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 88
Target Pharma Extends Agreement with Bristol-Myers Squibb 89
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 90
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 91
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 92
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 93
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 94
AbbVie and Bristol-Myers Squibb Enter into Agreement 95
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 96
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 97
Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 98
Oncodesign Enters into Agreement with Bristol-Myers Squibb 99
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 100
Bristol-Myers Squibb Enters into Agreement with Ohio State University Comprehensive Cancer Center 101
IFM Therapeutics to Enter into Research Agreement with University of Michigan 102
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 103
Bristol-Myers Squibb Enters into Research Agreement with UCLA 104
Bristol-Myers Squibb Enters into Research Agreement with Princeton University 105
Bristol-Myers Squibb Enters into Research Agreement with NCCN 106
Bristol-Myers Squibb Enters into Research Agreement with Sidney Kimmel Comprehensive Cancer Center 107
Bristol-Myers Squibb Enters into Research Agreement with Medical University of South Carolina 108
Bristol-Myers Squibb Enters into Agreement with uniQure 109
Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 110
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 111
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 112
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 113
OliPass Enters into Co-Development Agreement with Bristol-Myers Squibb 116
Bristol-Myers Squibb Enters into Agreement with Celgene 117
Bristol-Myers Squibb Forms Joint Venture with Allied Minds 118
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 119
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 121
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 122
Evotec Enters into Agreement with Padlock Therapeutics 123
Evotec Extends Agreement with Padlock Therapeutics 124
Immuneering Enters Into Agreement With Bristol-Myers Squibb For New Medicines 125
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 126
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 127
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 128
Ambrx Enters Into Co-Development Agreement With Bristol-Myers Squibb 130
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 131
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 132
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 133
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson's Disease 134
Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs 135
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 136
Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb 137
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University 138
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 139
Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 140
Licensing Agreements 141
Bristol-Myers Enters into Licensing Agreement with Domain Therapeutics 141
Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 142
Ayala Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 143
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 144
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 145
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 146
CN Bio Innovations Forms Licensing Agreement with Bristol-Myers Squibb 147
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 148
Bristol-Myers Squibb Enters into Licensing Agreement with PsiOxus Therapeutics 149
Bristol-Myers Squibb Enters into Licensing Agreement with Enterome 150
Bristol-Myers Squibb Enters into Licensing Agreement with Nitto Denko 151
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 152
Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 153
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 155
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 156
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 157
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 159
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 160
Bristol-Myers Squibb Enters into Licensing Agreement with QIMR Berghofer Medical Research Institute 161
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 162
Padlock Therapeutics Enters into Licensing Agreement with GlaxoSmithKline 163
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 164
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 165
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 166
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 167
Padlock Therapeutics Enters into Licensing Agreement with Scripps Research Institute 168
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 169
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 170
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 172
Medicines Patent Pool Extends Licensing Agreement With Bristol-Myers Squibb 174
Reckitt Benckiser Amends Licensing Agreement With Bristol-Myers Squibb For OTC Brands 175
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 177
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 179
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 180
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 181
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 182
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 183
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 184
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 185
Medicines Patent Pool Enters into Licensing Agreement with Bristol-Myers Squibb For Daclatasvir 187
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 188
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 189
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 190
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 191
Chiromics Enters Into Licensing Agreement With Bristol-Myers Squibb For Chemical Compounds 192
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 193
Equity Offering 194
Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 194
uniQure Raises USD38 Million in Private Placement of Shares 196
Debt Offering 197
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 197
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 199
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1% Notes Due 2025 201
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1.75% Notes Due 2035 202
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2019 For USD 500 Million 203
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2023 For USD 500 Million 205
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2044 For USD 500 Million 207
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For USD 500 Million 209
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For USD 750 Million 211
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For USD 750 Million 213
Asset Transactions 215
SK Biotek Acquires API Manufacturing Facility from Bristol-Myers Squibb for USD165 Million 215
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 216
Reckitt Benckiser Exercises Option to Acquire OTC Products of Bristol-Myers Squibb for USD317 Million 217
ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 218
ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 219
The CPP Investment Acquires Royalty Rights from Bristol-Myers Squibb 220
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 221
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 222
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 223
Bristol-Myers Squibb Reportedly To Sell Plavix And Avapro For USD 750 Million 224
Emcure Pharma Acquires Rights of BiCNU Injection from Bristol-Myers Squibb 225
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 226
Acquisition 227
Bristol-Myers Squibb Acquires IFM Therapeutics 227
Bristol-Myers Squibb Acquires Cormorant Pharma 228
Bristol-Myers Squibb Acquires Padlock Therapeutic 229
Bristol-Myers Squibb Acquires Cardioxyl Pharma for up to USD2.1 Billion 230
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 231
Bristol-Myers Squibb Acquires Flexus Biosciences for up to USD1.25 Billion 233
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 234
Pfizer May Acquire Bristol-Myers Squibb 235
Bristol-Myers Squibb Acquires iPierian 236
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For USD 4.3 Billion 237
Bristol-Myers Rumored To Acquire Biogen Idec 239
Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For USD 5.3 Billion 240
Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For USD 2.5 Billion 242
Bristol-Myers Squibb Co - Key Competitors 245
Bristol-Myers Squibb Co - Key Employees 246
Bristol-Myers Squibb Co - Locations And Subsidiaries 248
Head Office 248
Other Locations & Subsidiaries 248
Joint Venture 254
Recent Developments 255
Strategy And Business Planning 255
Nov 01, 2017: Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York 255
Financial Announcements 256
Jul 26, 2018: Bristol-Myers Squibb Reports Second Quarter Financial Results 256
Feb 05, 2018: Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results 258
Oct 26, 2017: Bristol-Myers Squibb Reports Third Quarter Financial Results 260
Jul 27, 2017: Bristol-Myers Squibb Reports Second Quarter Financial Results 262
Apr 27, 2017: Bristol-Myers Squibb Reports First Quarter Financial Results 265
Jan 26, 2017: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results 268
Corporate Communications 271
Aug 28, 2018: Bristol-Myers Squibb names Christopher Boerner as executive vice president and chief commercial officer 271
Jul 23, 2018: Bristol-Myers Squibb announces resignation of Murdo Gordon as Chief Commercial Officer 272
Mar 01, 2018: Bristol-Myers Squibb Names Jose Baselga, M.D., Ph.D. to Board of Directors 273
Oct 09, 2017: Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine 274
Sep 13, 2017: Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors 275
Apr 12, 2017: NICE's draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says 276
Mar 08, 2017: Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer 277
Feb 21, 2017: Bristol-Myers Squibb Appoints Three New Independent Directors 279
Government and Public Interest 280
May 11, 2018: Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer Outcomes 280
May 10, 2018: New Grants Totaling $2.6 Million Fund Work to Reduce Immunotherapy Side Effects 281
May 02, 2018: 2cureX's CEO Ole Thastrup will join Folkemodet 2018 in Denmark 282
Oct 26, 2017: Study to test combination therapy for breast cancer 283
Sep 08, 2017: Major breakthroughs spell hope for melanoma patients 284
Product News 285
12/12/2017: PsiOxus Therapeutics Receives $15M Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA 285
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 286
10/04/2017: Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORC Inverse Agonist Program 288
06/14/2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017) 289
06/04/2017: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting 290
06/03/2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy 291
May 14, 2018: Researchers test flexible cancer research model 293
May 02, 2018: BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace 294
04/20/2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting 295
03/13/2017: Expansion Of Phase I/II Trial Evaluating Lirilumab In Combination With Opdivo (Nivolumab) In Patients With Advanced Solid Tumors 296
Product Approvals 297
Jun 21, 2018: U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden =10 mut/Mb 297
Nov 28, 2017: CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic 298
Jan 24, 2017: European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis 299
Clinical Trials 300
Sep 12, 2018: Bristol-Myers Squibb's novel, oral, selective TYK2 inhibitor delivered significant skin clearance in patients with moderate to severe plaque psoriasis in phase 2 trial 300
Jul 10, 2018: Exalenz Bioscience's Non-Invasive BreathID Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH 302
Oct 20, 2017: Bristol-Myers Squibb to Present New Data on its liver disease drug candidate BMS-986036 at The Liver Meeting 2017 303
Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial 304
Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis 305
Apr 03, 2017: Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting 306
Feb 15, 2017: ASLAN Pharmaceuticals' new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine 307
Feb 06, 2017: INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab 308
Other Significant Developments 309
Aug 07, 2018: Melanoma Research Alliance announces new funding opportunity for research to accelerate progress toward curing melanoma 309
Aug 06, 2018: Scripps Research and Bristol-Myers Squibb scientists create atomic glue gun to build better nucleic acid therapeutics 310
May 31, 2017: PeptiDream Announces 5 th Milestone from Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb 312
Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre 313
Appendix 314
Methodology 314
About GlobalData 314
Contact Us 314
Disclaimer 314
List of Figure
List of Figures
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 14
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16
Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 18
List of Table
List of Tables
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15
Bristol-Myers Squibb Co, Deals By Therapy Area, 2012 to YTD 2018 16
Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 18
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 31
IFM Tre Raises USD31 Million in Series A Venture Financing 33
Enterome Bioscience Raises USD38.5 Million in Series D Financing 34
TARIS Biomedical Raises USD25 Million in Series B Financing 36
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 38
Cardior Pharma Raises USD16.3 Million in Series A Financing 40
IFM Therapeutics Raises USD27 Million in Series A Financing Round 42
Blade Therapeutics Raises USD27 Million in Series B Financing 43
IFM Therapeutics Raises Funds in Seed Financing Round 45
Padlock Therapeutics Raises USD23 Million in Extended Series A Financing 46
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 47
iPierian Raises USD1 Million in Venture Financing 48
Padlock Therapeutics Raises Funds through Series A Financing 49
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 50
iPierian Raises USD 30 Million In Series A Venture Financing 51
Cormorant Pharma Raises USD 2.6 Million In Venture Financing 53
Cardioxyl Pharma Raises USD 28 Million In Series B Financing 54
Bristol-Myers Squibb May Sell UPSA to BC Partners, CVC Capital, PAI Partners and STADA for USD1.16 Billion 55
Bristol-Myers Squibb and Tsinghua University Enter into Co-Development Agreement 57
Bristol-Myers Squibb and Gritstone Oncology Enter into Research Agreement 58
Clinigen and Bristol-Myers Squibb Enter into Agreement 59
Bristol-Myers Squibb Expands Collaboration with Flatiron Health 60
Advantagene Enters into Agreement with Bristol-Myers Squibb 61
Lupus Therapeutics Enters into Agreement with Bristol-Myers Squibb 62
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 63
Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 64
Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 65
Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 66
Replimune Enters into Co-Development Agreement with Bristol-Myers Squibb 68
Sirenas Enters into Research Agreement wiith Bristol-Myers Squibb 69
Taris Biomedical and Bristol-Myers Squibb Enter into Partnership 70
Bristol-Myers Squibb Enters into Research Agreement with Kumamoto University 71
AbbVie and Bristol-Myers Squibb Enter into Agreement 72
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 73
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 74
Bristol-Myers Squibb Enters into Partnership with Novartis 75
Bristol-Myers Squibb and Qiagen Enter into Agreement 76
Advaxis and Bristol-Myers Squibb Enter into Agreement 77
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 78
Bristol-Myers Squibb Enters into Research Agreement with Transgene 79
Bristol-Myers Squibb Enters into Agreement with Nordic Bioscience 80
Bristol-Myers Squibb Enters into Agreement with Apexigen 81
Bristol-Myers Squibb and Incyte Enter into Agreement 82
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 83
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 84
Exelixis Enters into Agreement with Bristol-Myers Squibb 85
Bristol-Myers Squibb Enters into Research Agreement with GeneCentric Diagnostics 86
Janssen Biotech Enters into Partnership with Bristol-Myers 87
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 88
Target Pharma Extends Agreement with Bristol-Myers Squibb 89
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 90
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 91
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 92
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 93
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 94
AbbVie and Bristol-Myers Squibb Enter into Agreement 95
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 96
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 97
Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 98
Oncodesign Enters into Agreement with Bristol-Myers Squibb 99
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 100
Bristol-Myers Squibb Enters into Agreement with Ohio State University Comprehensive Cancer Center 101
IFM Therapeutics to Enter into Research Agreement with University of Michigan 102
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 103
Bristol-Myers Squibb Enters into Research Agreement with UCLA 104
Bristol-Myers Squibb Enters into Research Agreement with Princeton University 105
Bristol-Myers Squibb Enters into Research Agreement with NCCN 106
Bristol-Myers Squibb Enters into Research Agreement with Sidney Kimmel Comprehensive Cancer Center 107
Bristol-Myers Squibb Enters into Research Agreement with Medical University of South Carolina 108
Bristol-Myers Squibb Enters into Agreement with uniQure 109
Bristol-Myers Squibb to Terminate R&D Agreement with Rigel Pharma 110
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 111
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 112
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 113
OliPass Enters into Co-Development Agreement with Bristol-Myers Squibb 116
Bristol-Myers Squibb Enters into Agreement with Celgene 117
Bristol-Myers Squibb Forms Joint Venture with Allied Minds 118
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 119
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 121
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 122
Evotec Enters into Agreement with Padlock Therapeutics 123
Evotec Extends Agreement with Padlock Therapeutics 124
Immuneering Enters Into Agreement With Bristol-Myers Squibb For New Medicines 125
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 126
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 127
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 128
Ambrx Enters Into Co-Development Agreement With Bristol-Myers Squibb 130
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 131
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 132
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 133
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson's Disease 134
Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs 135
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 136
Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb 137
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University 138
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 139
Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 140
Bristol-Myers Enters into Licensing Agreement with Domain Therapeutics 141
Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 142
Ayala Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 143
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 144
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 145
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 146
CN Bio Innovations Forms Licensing Agreement with Bristol-Myers Squibb 147
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 148
Bristol-Myers Squibb Enters into Licensing Agreement with PsiOxus Therapeutics 149
Bristol-Myers Squibb Enters into Licensing Agreement with Enterome 150
Bristol-Myers Squibb Enters into Licensing Agreement with Nitto Denko 151
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 152
Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 153
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 155
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 156
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 157
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 159
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 160
Bristol-Myers Squibb Enters into Licensing Agreement with QIMR Berghofer Medical Research Institute 161
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 162
Padlock Therapeutics Enters into Licensing Agreement with GlaxoSmithKline 163
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 164
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 165
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 166
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 167
Padlock Therapeutics Enters into Licensing Agreement with Scripps Research Institute 168
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 169
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 170
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 172
Medicines Patent Pool Extends Licensing Agreement With Bristol-Myers Squibb 174
Reckitt Benckiser Amends Licensing Agreement With Bristol-Myers Squibb For OTC Brands 175
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 177
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 179
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 180
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 181
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 182
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 183
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 184
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 185
Medicines Patent Pool Enters into Licensing Agreement with Bristol-Myers Squibb For Daclatasvir 187
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 188
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 189
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 190
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 191
Chiromics Enters Into Licensing Agreement With Bristol-Myers Squibb For Chemical Compounds 192
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 193
Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 194
uniQure Raises USD38 Million in Private Placement of Shares 196
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 197
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 199
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1% Notes Due 2025 201
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1.75% Notes Due 2035 202
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2019 For USD 500 Million 203
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2023 For USD 500 Million 205
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2044 For USD 500 Million 207
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For USD 500 Million 209
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For USD 750 Million 211
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For USD 750 Million 213
SK Biotek Acquires API Manufacturing Facility from Bristol-Myers Squibb for USD165 Million 215
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 216
Reckitt Benckiser Exercises Option to Acquire OTC Products of Bristol-Myers Squibb for USD317 Million 217
ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 218
ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 219
The CPP Investment Acquires Royalty Rights from Bristol-Myers Squibb 220
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 221
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 222
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 223
Bristol-Myers Squibb Reportedly To Sell Plavix And Avapro For USD 750 Million 224
Emcure Pharma Acquires Rights of BiCNU Injection from Bristol-Myers Squibb 225
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 226
Bristol-Myers Squibb Acquires IFM Therapeutics 227
Bristol-Myers Squibb Acquires Cormorant Pharma 228
Bristol-Myers Squibb Acquires Padlock Therapeutic 229
Bristol-Myers Squibb Acquires Cardioxyl Pharma for up to USD2.1 Billion 230
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 231
Bristol-Myers Squibb Acquires Flexus Biosciences for up to USD1.25 Billion 233
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 234
Pfizer May Acquire Bristol-Myers Squibb 235
Bristol-Myers Squibb Acquires iPierian 236
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For USD 4.3 Billion 237
Bristol-Myers Rumored To Acquire Biogen Idec 239
Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For USD 5.3 Billion 240
Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For USD 2.5 Billion 242
Bristol-Myers Squibb Co, Key Competitors 245
Bristol-Myers Squibb Co, Key Employees 246
Bristol-Myers Squibb Co, Subsidiaries 248
Bristol-Myers Squibb Co, Joint Venture 254
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.